18 December 2025 : Clinical Research
Optimizing Nivolumab Efficacy: The Role of Dosing Time in Advanced Non-Small Cell Lung Cancer
Mustafa Ersoy
ABEF 1*
DOI: 10.12659/MSM.950963
Med Sci Monit 2025; 31:e950963
Table 4 Immune-related adverse effects by treatment time and adverse effect type.
| Treatment time | Adverse effect | N | Grade(s) | Adverse effect present | Adverse effect absent | P value |
|---|---|---|---|---|---|---|
| Received before 1 PM | Thyroiditis | 1 | 1 | 4 | 26 | .273 |
| Colitis | 1 | 1 | ||||
| Rash | 1 | 1 | ||||
| Elevated liver enzymes | 1 | 1 | ||||
| Received after 1 PM | Thyroiditis | 1 | 2 | 6 | 18 | |
| Colitis | 2 | 2 | ||||
| Rash | 2 | 2 | ||||
| Fever | 1 | 2 | ||||
| – number of patients. The value was calculated using the Pearson chi-square test. Significance was set at | ||||||